Boston Sci heralds Emerge launch in Europe, eyes U.S., other markets

Coming off the news of its defibrillator issues (see related story) Boston Scientific ($BSX) had some good news this morning. The devicemaker has received CE mark approval and witnessed the European market launch of the Emerge PTCA dilatation catheter. The company is hoping the product will become available in the U.S. and other markets later this year. "The Emerge catheter combines several innovative balloon technologies in a single versatile platform," explains Jean Fajadet, who performed the first procedure in Europe with the catheter. "The result is a functional catheter with a low profile and excellent deliverability to facilitate the navigation and crossing of challenging coronary lesions." Boston Scientific release

Suggested Articles

Sherlock Biosciences teamed up with Cepheid to help develop its CRISPR-based molecular diagnostic tech in oncology, infections and the coronavirus.

The spine surgery company ATEC has moved to acquire Paris-based EOS imaging, makers of FDA-cleared scanners and 3D orthopedic planning software.

Digital molecule designer Insilico Medicine has launched a new preclinical research program focused on treatments for brain cancer.